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Abstract
Short tandem repeats (STRs) and single nucleotide polymorphisms (SNPs) have been
already used to perform noninvasive prenatal paternity testing frommaternal plasma
DNA. The frequently used technologies were PCR followed by capillary electrophoresis
and SNP typing array, respectively. Here, we developed a noninvasive prenatal paternity
testing (NIPAT) based on SNP typing with maternal plasma DNA sequencing. We evalu-
ated the influence factors (minor allele frequency (MAF), the number of total SNP, fetal
fraction and effective sequencing depth) and designed three different selective SNP pan-
els in order to verify the performance in clinical cases. Combining targeted deep sequenc-
ing of selective SNP and informative bioinformatics pipeline, we calculated the combined
paternity index (CPI) of 17 cases to determinepaternity. Sequencing-based NIPAT results
fully agreed with invasive prenatal paternity test using STRmultiplex system. Our study
here proved that the maternal plasma DNA sequencing-based technology is feasible and
accurate in determiningpaternity, which may provide an alternative in forensic application
in the future.
Introduction
The discovery of cell-free fetal DNA (cffDNA) in maternal blood in 1997 provides the possibil-
ity to develop novel noninvasive prenatal paternity testing, which can avoid the procedure-
associated fetal loss as well as the restriction of sampling time [1]. In recent years, a few
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research groups reported pilot studies about noninvasive genotyping of maternal plasma DNA
using short tandem repeat (STR) and single-nucleotide polymorphisms (SNP) for paternity
determination. In 2009, Jasenka et al. first developed a method based on capillary electrophore-
sis (CE) detection of STR markers in maternal plasma DNA for noninvasive prenatal paternity
test [2]. In their study, only 1–6 informative autosomal STR loci were obtained in 20 pregnan-
cies (13 with male fetus and 7 with female fetus) and 6–16 Y-STR loci could be observed in 13
pregnancies with male fetus. Without enough effective STR loci, it was hard to make a trustful
paternity determination. Then in 2011, Tynan et al. used SNP genotype basedmethod to
obtain 5–20 paternal alleles in plasma DNA from 154 pregnancies and provided a potential use
for noninvasive prenatal paternity testing [3]. In 2012, Guo et al. used allele-specificPCR to
observe the difference of biological father and unrelated man and describe the basic require-
ment of informative SNP for paternity exclusion [4]. In 2013, Ou et al. usedmethylation-sensi-
tive restriction enzyme to enrich the fetal DNA at rs4688725 and suggested that more effective
marker should be selected for paternity testing in the future [5, 6]. In 2013, Ryan et al. used
HumanCytoSNP-12 array chip (~ 300,000 SNPs) to perform genotyping of paternal alleles in
maternal plasma DNA and set up the normal distribution of 1821 unrelated males [7]. With p-
value< 0.0001, 20 out of 21 pregnancies were successfully determined and only one case
undetermined.
Here, we combinedmassively parallel sequencing and SNP-based method together and
developed a novel sequencing-basednoninvasive paternity testing (NIPAT). We performed
systematic evaluation of influencing factors, such as the SNP frequency, required number of
effective SNP, sequencing depth, threshold of fetal fraction, as well as sequencing strategy. We
validated the reliability of this sequencing-basedNIPAT in real clinical samples, thus showing
the feasibility of using NIPAT in a clinical setting.
Materials andMethods
General study design
We designed a two-stage study to evaluate the performance of the noninvasive prenatal pater-
nity testing (NIPAT) based on maternal plasma DNA sequencing. In Phase I, one case was
recruited to initiate methodologydevelopment and described the characteristics such as several
affecting factors. In Phase II, 16 clinical pregnancies were recruited to optimize and validate
the feasibility in selected SNP panels and established the quality control system. Finally, we
chose the best panel for further validation in real clinical pregnancies. An overviewof the study
workflow is showed in Fig 1.
Fig 1. The studyworkflow. Therewere two stages in this study. The first stage determined the criteriaof SNP panel selection based on the
evaluation results from simulation data. The second stage was clinical validation in 16 real pedigrees using three different selective SNP panels.
doi:10.1371/journal.pone.0159385.g001
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Sample collection and parenthood determination
Seventeen families were recruited from the collaborative hospitals. The gestational age (GA)
ranged from 13 to 30+6 weeks and the maternal age from 26 to 44 years old. Two-milliliter
peripheral blood samples of pregnant women and their husbands were collected into EDTA-
containing tubes. Maternal plasma was isolated with a two-step centrifugation protocol [8].
Amniocentesis was performed at 18-20th weeks and five milliliters amniotic fluid was obtained
from the hospitals. 100 microliters blood samples from both parents and 500 microliters amni-
otic fluid from 5 families were sent to ShenzhenMunicipal Public Security Bureau (Shenzhen,
China) for conventional prenatal paternity test using the AmpFlSTR1Identifiler1 PCR Ampli-
fication Kit (ABI). Meanwhile, sequencing data of 90 unrelated healthy Han Chinese were
downloaded from the 1000 Genomes Project (BioProject ID:298320). Detailed pedigree infor-
mation of all families is listed in Table A in S3 File.
Informed written consent was obtained from each participant. This study was approved by
the institutional review board of BGI-Shenzhen and conducted in accordance with the Declara-
tion of Helsinki.
DNA extraction, Library preparation
Genomic DNA (g-DNA) of parents and amniotic fluids was extracted with QIAamp DNA
Mini Kit (Qiagen) following the manufacturer’s instructions.One microgram g-DNA was frag-
mented by sonication (Covaris). CffDNA in maternal plasma was extracted from 200-microli-
ter maternal plasma by TIANamp Micro DNA Kit (Tiagen) and the DNA was already
fragmented by nature. After end blunted, all fragments were added an “A” tail for the ligation
with adaptors. Barcodes were introduced during PCR for multiplex sequencing.
Three customer-designed panels were obtained fromNimbleGen (Roche). DNA libraries
were measured with Agilent 2100 bioanalyzer (Agilent) for insert size and quantified by real-
time PCR. Three microgramDNA libraries were hybridized to the SNP panels according to the
manufacturer’s instructions [9]. Captured DNA libraries were conducted using 90bp paired-
end index sequencing on HiseqTM 2000 (Illumina) according to the manufacturer’s
instructions.
Reads alignment and SNP calling
The paired-end sequencing reads were mapped to the human reference genome (Hg19,
GRCh37) using SOAP2 [10]. The reads that mapped to multiple locations and the duplication
reads were removed. SNP calling was performed using the SOAPsnp software in the target
region or whole-genomewide [11]. The filter criteria (coverage greater than 8 and quality value
higher than 20) were set to guarantee the accuracy of the genomic genotype.Meanwhile, error
rate was recorded for quality control purpose before CPI calculation.
When the locus was homozygous in both parents with the same genotypes, we defined error
as the situation that the fetal genotype was unexpectedheterozygote based on Mendel’s law.
The formula f error ¼
derror
dmotherþderror
was used to calculate the error rate in maternal plasma (ferror),
where dmother and derror stand for the depth of allele frommother and error (all other alleles
which was different frommother’s genotype) respectively.
Estimation of fetal fraction
For locus homozygous in both parents but with different genotypes, the fetal genotype was an
obligate heterozygote based on Mendel’s laws. Thus fetal fractionwas calculated using the
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formula f ¼ 2dfatherdmotherþdfather , where dfather and dmother stand for the depth of allele from father and
mother respectively.
Mathematicalmodel of SNP-based paternity test
We developed a novel algorithm to describe the paternity index (PI) of a male candidate in a
random population based on the effective SNP (the SNP homozygous in mother) in maternal
plasma sequencing data. This value was defined as the odds ratio in the formula: PI ¼ XY. In this
formula, X = Pr(Plasma|Mother,T), which stands for the probability that male candidate is the
biological father; and Y = Pr(Plasma|Mother,R), which stands for the probability of that a ran-
domman is the biological father. According to the Bayesian model, the PI was calculated as:
PI ¼
X
Y
¼
PrðPlasmajMother ;TÞ
PrðPlasmajMother ;RÞ
¼
PrðPlasma; FetusjMother ;TÞ
PrðPlasma; FetusjMother ;RÞ
¼
X
Fetus
PrðFetusjMother ;TÞPrðPlasma; FetusjMother ; Fetus; TÞ
X
Fetus
PrðFetusjMother ;RÞPrðPlasma; FetusjMother ; Fetus; RÞ
Thus the combined paternity index (CPI) was calculated as the product of PI: CPI ¼
Y
i¼1
PIi
Moreover, the probability of every candidate fetal genotype (Pr(Fetus|Mother,Father )) was
calculated by the Mendel’s Law and independent assortment. The probability of the depth dis-
tribution in maternal plasma corresponding to different combination of mother and fetus was
calculated by quadrinomial distribution, described as:
PrðPlasma; FetusjMother ; Fetus; FatherÞ ¼
n!
aA!aT !aC!aG!
paAA p
aT
T p
aC
C p
aG
G
Where aXmeans the effective sequencing depth of base X; pXmeans the incidence rate of
base X, obtained from theoretical probability of occurrence.Additionally, we performed test
statistic with 90 unrelated individuals and calculated the p-value [7, 12]. We defined that when
the logarithm of CPI (Lg(CPI)) was greater than 4 and p-value<10−4, the alleged father was
classified as biological father.
Results
Systematic evaluation of influence factors to NIPAT
First, we evaluated the influence of MAF to sequencing-basedNIPAT. In our bioinformatics
pipeline, the binomial distribution was suited to the frequency distribution of the effective SNP
in NIPAT. According to the binomial distribution probability model, there was a positive cor-
relation betweenMAF, the number of total SNP and the number of effective SNP (S1 Fig). To
further validate the theory, WGS was performed in S01 (effective sequencing depth of 37.37X)
and the obtained SNPs were divided into two groups, namely the high frequency (HF, refers to
MAF>0.3 on db135) and low frequency (LF, refers to MAF<0.3 on db135). Although the
number of effective SNPs in LF was 1.72 times more than effective SNPs in HF (1.95×106 vs
1.1336×106) inWGS data of S01 plasma, the calculated Lg(CPI) were 9.88×104 and -8.53×104,
the error rate were 3.79‰ and 3.20‰, respectively. This preliminary result based showed that
for sequencing-basedNIPAT, only HF SNPs worked well with not enough deep sequencing
Noninvasive Prenatal Paternity Test
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depth (40.06X for HF SNPs and 34.68X for LF SNPs). This outcome was consistent with previ-
ous study of invasive paternity test [13].
Based on above results, HF SNPs were chosen for NIPAT. To evaluate the other factors
affectingNIPAT, simulating sequencing data with consistent error rate was generated using
the sequencing data of S01 (maternal g-DNA and amniotic fluid g-DNA). These simulation
data had three situations: 1) with 75X sequencing depth, the number of effective SNPs ranged
from 10 ~1×105, and the fetal fraction from 1% to 30%; 2) with 10% fetal fraction, the number
of effective SNP ranged from 10~1×105 and the effective sequencing depth from 10X~2×103X;
3) with 1×103 effective SNPs, the fetal fraction ranged from 1%-30% and the effective sequenc-
ing depth from 10X~2×103X.
First, the simulated data with the effective sequencing depth of 75X was generated to evalu-
ate the effect of fetal fraction.With the fetal fraction increasing from 1% to 30%, the calculated
Lg(CPI) increased from 3.34 (-1.52~-10.74) to 91.84 (30.79~157.30) when the number of effec-
tive SNP was 1×103, thus showing significant positive correlation between calculated CPI and
fetal fraction. Fetal fraction showed considerable influence to CPI when changed from 1% to
10%. However, once above 10%, fetal fraction had little effect to the calculated CPI (Fig 2A).
With the effective sequencing depth of 75X, the samples with fetal fraction less than 3% were
applicable for sequencing-basedNIPAT when the number of effective SNP number was over
1×105 (S2 Fig).
Second, we evaluated the effect of sequencing depth at the fixed fetal fraction of 10%.With
effective sequencing depth increasing from 10X to 200X, the calculated Lg(CPI) increased from
-113.66 (-239.24~-21.91) to 90.95 (36.97~150.90) when the number of effective SNP was
1×103, showing a strong positive correlation. The change of effective sequencing depth from
10X to 75X brought obvious improvement of calculated CPI, whereas further increase of effec-
tive sequencing depth only slightly improved the calculated CPI. In particular, sequencing
depth over 200X did not improve the calculated CPI any more (Fig 2B). Additionally, we
observed that the calculated Lg(CPI) was below zero and the determination of paternity was
incorrect if the sequencing depth dropped below 30X, no matter how many effective SNPs
were used (S3 Fig). For low fetal fraction (~1%) samples, deep sequencing (>125X) or
increased number of effective SNP (N>1×105) was recommend (Fig 2C and 2D).
Based on above results, the following conditions were determined for sequencing-based
NIPAT: 1×103~2×103 effective SNPs (5×103−8×103 total SNPs in designed panel), MAF of the
SNPs greater than 0.3, sequencing depth over 75X, and fetal fraction over 3%. In the condition
of fetal fraction less than 3%,>125X sequencing depth was recommended.We firstly per-
formed our bioinformatics pipeline in S01 plasmaWGS data to validate the applicability of this
method. The calculated Lg(CPI) for NIPAT based on our bioinformatics pipeline in S01 by
using effectiveHF SNP was 9.88×104 and the p-value was< 10−4. Meanwhile, the calculated Lg
(CPI)for amniotic fluid was 2.92×104 and the p-value was< 10−4. With Lg(CPI)> 4 and p-
value<0.01, we defined the S01 alleged father as biological father, which was consistent with
the results based on invasive paternity test (Fig 3).
Clinical validation and influence factors evaluation using real
sequencing data
Clinical validation in three customer-designedSNP panels. Based on simulation results,
three customer-designed SNP panels were obtained from NimbleGen (Roche) for further vali-
dation of our sequencing-basedNIPAT method in clinical samples. Array-HLF663243 con-
tained 3.330×106 LF and 6.63×105 HF SNPs; Array-HF8242 included 8.24×103 HF SNPs, and
Array-HF5011 contained 5.01×103 HF SNPs.
Noninvasive Prenatal Paternity Test
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Fig 2. Systematic evaluation of influence factors to sequencing-basedNIPAT. (A) In given conditions (1000 effective SNPs and 75X sequencing
depth), when the fetal fraction increased from 1% to 10%, the CPI increased dramatically; while once fetal fraction reached to 10%, the calculatedCPI
increased slightly. (B) In given conditions (1000 effective SNPs, 10% fetal fraction), the initial effective sequencing depth changed from 10X to 75X
resulted in a dramatic increase of calculatedCPI, whereas the following effective sequencing depth change only brought week increase of calculatedCPI,
and stay stable when the sequencing depth was over 200X. (C) In special conditions (1% fetal fraction, 1000 effective SNPs), deep sequencing (>125X)
was recommend for NIPAT. (D) In special conditions (1% fetal fraction, 75X sequencing depth), a larger number of effective SNPs (>10000)was
recommend for NIPAT.
doi:10.1371/journal.pone.0159385.g002
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The sequencing depth of g-DNA and cffDNA of each family was 26~350 folds and 40–400
folds respectively (Table B in S3 File). The number of theoretically informative SNPs accounted
for about 40% of total SNPs in each selective SNP panels (Table B in S3 File). The calculated
fetal fractionwere 16.65% (7.83~29.74%) in 16 plasma samples (Table 1). The calculated Lg
(CPI) for NIPAT based on our bioinformatics algorithm for the biological father and unrelated
males were 2.7888×103 (176.78~1.55×104) and -4.5534×103 (-2.87×104~ -153.72) respectively.
11.6% (4.2%~15.4%) of effective SNPs assignedwrongly from the pool of potentially informa-
tive SNPs for a tangible parents (Table C in S3 File). The error rate for the biological father and
Fig 3. Combined Paternity Index (CPI) in biologic father and randommen. The x-axis stands for the sample ID in the top and
the bottom; the y-axis marks the logarithmic value of CPI in the left and the right. The logarithm of CPI calculated from 17 real
sampleswere over four, and had a significant separate distribution of CPIs between the biological father and 90 unrelated
individuals.
doi:10.1371/journal.pone.0159385.g003
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unrelated males were 3.76‰ (2.08‰~5.28‰) and 10.94‰ (5.57‰~28.78‰), respectively.
The p-value for the alleged father was all< 10−4 (Table 1). We observed significant separation
of distribution of CPIs and UHM error between the biological father and unrelated males (Fig
3), suggesting the successful identification of the correct biological father.
To verify our results of paternity decision in NIPAT, we performed our bioinformatics
method based on amniotic fluid sequencing data of each family. The calculated Lg(CPI) of the
biological father and unrelated males were 5.51×103 (195.28~2.73×104) and -6.31×104
(-3.39×105~-1.19×104) respectively. The error rate for biological father and unrelated males
were 2.29‰ (1.33‰~4.36‰) and 41.55‰ (6.27‰~93.89‰), respectively (Table 1). Interest-
ingly, the number of effective SNPs in NIPAT from plasma DNA sequencing and AF DNA
sequencing was similar, 1.756×104 (818~9.17×104) and 1.97×104 (872~1.04×104), respectively
(Table D in S3 File). We showed that maternal plasma sequencing-basedNIPAT could
obtained 93.546% (86.21~98.82%) of total effective SNPs in maternal plasma DNA to calculate
CPI and determine paternity, which means that sequencing-basedNIPAT can obtain similar
number of effective SNPs from plasma as from amniotic fluid. Furthermore, the number of
effective SNPs had a positive relationship with the number of total SNP in designed array
(Table 1), which was consistent with the evaluation results above (S1 Fig).
Seventeen cases underwent sequencing-basedpaternity test using fetal DNA from amniotic
fluid cells. The NIPAT results were 100% (17/17) consistent with the results from invasive paternity
Table 1. The results of noninvasive prenatal paternity test.
Sample Fetal
fraction
Error rate in
plasma
Error rate in
AF1
Lg(CPI)2(Plasma) NIPAT 3 Results Lg
(CPI)2(AF1)
Conventional
Paternitytesting results
LF4 HF5 Paternity
Inclusion
p-value HF5 CPI6 Paternity
Inclusion
S01 5.84% 0.38% 0.30% -8.5256×104 9.8774×104 Yes <0.0001 2.9172×104 / Yes
S02 7.83% 0.35% 0.40% 3.9466×103 1.1741×104 Yes <0.0001 2.6583×104 / Yes
S03 14.45% 0.30% 0.31% 6.4066×103 1.5523×104 Yes <0.0001 2.7091×104 / Yes
S04 14.26% 0.31% 0.44% 3.4925×103 1.3236×104 Yes <0.0001 2.7330×104 / Yes
S05 14.86% 0.49% 0.20% / 292.29 Yes <0.0001 768.28 1.858×107 Yes
S06 20.21% 0.51% 0.21% / 446.55 Yes <0.0001 584.22 8.6138×106 Yes
S07 23.97% 0.53% 0.15% / 230.99 Yes <0.0001 549.33 2.9538×107 Yes
S08 11.52% 0.50% 0.20% / 428.71 Yes <0.0001 621.84 6.6091×107 Yes
S09 17.55% 0.35% 0.19% / 416.1 Yes <0.0001 623.85 / Yes
S10 10.44% 0.25% 0.16% / 326.4 Yes <0.0001 569.62 / Yes
S11 9.34% 0.37% 0.14% / 199.22 Yes <0.0001 536.24 / Yes
S12 16.52% 0.35% 0.16% / 248.57 Yes <0.0001 406.28 / Yes
S13 18.86% 0.42% 0.22% / 335.93 Yes <0.0001 832.35 / Yes
S14 17.93% 0.31% 0.21% / 454.49 Yes <0.0001 746.78 / Yes
S15 15.78% 0.41% 0.20% / 215.84 Yes <0.0001 427.99 / Yes
S16 29.74% 0.21% 0.13% / 348.83 Yes <0.0001 364.06 / Yes
S17 23.16% 0.36% 0.27% / 176.78 Yes <0.0001 195.28 9.0089×105 Yes
1:AF: amniotic fluid
2:Lg(CPI): the logarithmof Combined Paternity Index
3:NIPAT :noninvasive prenatal paternity testing
4:LF:Minor Allele Frequency of SNP <0.3
5:HF:Minor Allele Frequency of SNP >0.32
6:CPI:Combined Paternity Index
doi:10.1371/journal.pone.0159385.t001
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test based on amniotic fluid sequencing data. Additionally, 5 in total of 17 cases had conventional
paternity test by CE STR, and also showed 100% consistency to NIPAT results (5/5) (Table 1).
Influence factors evaluation using real sequencing data. Sequencing data from ten fami-
lies tested by Array-HF8242 was used to study the four influencing factors to verify the findings
from simulation data. We extracted sequencing data from this real clinical plasma sequencing
data based on controlling variables method.
First, we evaluated the influence of the number of effective SNP with fixed effective sequenc-
ing depth (75X). There was no significant correlation betweenCPI or the number of effective
SNPs and the fetal fractionwith the same effective sequencing depth (75X) and fetal
fraction>10% (Fig 4A and 4B, Table E in S3 File). Second, with the fixed number of total SNPs,
there was no obvious correlation between the effective sequencing depth and the number of
effective SNPs. However, the calculated Lg(CPI) increased from -166.94 to 403.62 with the
effective sequencing depth increasing from 25X to 150X (Table E in S3 File). Notably, the cal-
culated Lg(CPI) had no marked increase when the effective sequencing depth reached 75X (Fig
4C and 4D). All above analysis results were consistent with the initial simulation data. Unfortu-
nately, only one family had fetal fraction lower than 10%. To verify the NIPAT performance at
low fetal fraction in real clinical case, we extracted data from S01 plasma (sequencing
depth = 40X, fetal fraction = 5.84% and the number of effective SNP from 10~1×108). We
observed that when effective sequencing depth was relative low (40X), the number of effective
SNPs should be larger than 1×105 for a highly accuracy (>99.99%) performance of NIPAT (S4
Fig). This result was consistent with previous evaluated results based on simulating data, which
was generated from the mother g-DNA and amniotic fluid genomic sequencing data.
Fig 4. Influence factors evaluation to Combined Paternity Index (CPI) based on real sample sequencingdata. (A) The number of
effective SNPs and the logarithmof CPI did not relate with the fetal fraction when fetal fraction over 10%. (B) Therewas no obvious
correlation between Paternity Index of each effective SNPs and fetal fraction. (C) The logarithmof CPI had a significant positive correlation
with effective sequencing depth, while the number of effective SNPs did not relate with effective sequencing depth. (D) The logarithmof PI
had a positive correlationwith the effective sequencing depth.
doi:10.1371/journal.pone.0159385.g004
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Discussion
Current STR-based paternity testing was applied for families with postpartum children (vinous
blood, saliva, hair, et al.) as well as prenatal fetus (CVS, Amniotic fluid and cord blood). For
special cases of prenatal testing, such as cases before the 8th week of pregnancy or contraindi-
cated patients with invasive procedures, a noninvasive prenatal paternity test would be useful
and necessary to give out a result. Since plasma cffDNA is fragmented, it is hard to obtain suffi-
cient effective loci of short tandem repeat (STR) to determine paternity by using commercial
STR typing kit, especially in female fetus[2]. Considering this, SNP-based noninvasive pater-
nity test could give more reliable information than STR-based method to calculate the com-
bined paternity index (CPI). The advantages of SNP-based noninvasive paternity test include:
1) applicable to short DNA fragments, 2) vast number of SNPs across the whole human
genome for analysis. Although a SNP-based method using a high-throughput SNP genotyping
array (HumanCytoSNP-12 array chip, ~ 300,000 SNPs) with maternal plasma DNA has been
reported for noninvasive paternity testing with high accuracy, a large amount of maternal
cffDNA (10mL plasma) was needed in order to get low signal-to-noise genotyping results and
aggregating sufficient effective SNPs to do paternity test[7]. Considering the limited probes at
each site of genotyping array(~30X) in Ryan’s study, it would miss several father-originated
alleles when fetal fraction is lower than 3% and it is impossible to get sufficient effective SNPs
in these cases for noninvasive paternity determination[7].Moreover, the influencing factors,
which affect the accuracy of noninvasive paternity testing, such as the allelic frequency of the
selected SNPs, the minimal number of total SNPs and the threshold of fetal fraction, remained
unevaluated.
Here, we developed a novel, robust and highly accurate maternal plasma DNA sequencing-
based noninvasive prenatal paternity testing (NIPAT) and successfully determined paternity in
17 real clinical cases. Furthermore, we evaluated the influence of the number of effective SNPs
(total SNPs in designed array), the MAF of SNPs, fetal fraction as well as effective sequencing
depth. We observed that the number of effective SNPs had a significant relationship with MAF
and the number of total SNPs. In addition, there are individual differences between pregnant
women, so the effective SNPs was not similar even using the same capture array. Meanwhile,
we systematically evaluated the influence of fetal fraction and effective sequencing depth to the
power of NIPAT. Based on our results, we suggested that for NIPAT, the general design should
be selecting SNPs with HFMAF of 0.3~0.5, the total number of HF SNP of 5×103~8×103, the
sequencing depth 75-200X, which could reach over highly accuracy (>99.9999% based on the
50,400 simulated samples) by using maternal plasma. There is a need for perform noninvasive
paternity test in first trimester, however the low fetal fraction (<3.5%) made it difficult to accu-
rate determine paternity. We simulated conditions with 1% fetal fraction, 8×103 total SNPs and
200X effective sequencing depth, and we accurately determined paternity frommaternal
plasma, providing basic data for NIPAT in first trimester by using our bioinformatics method.
There were some limitations in our study. First, all our recruited samples were in the second
trimester (12-20th week) with relatively high fetal fraction (5.68%~29.74%). Further study
should be performedwith samples in the first trimester (<12th week) with lower fetal fraction.
Second, the SNP was selected from db135 with MAF>0.3, validated only in Chinese popula-
tion. Other ethnic groups need to be verified in the subsequent study. Last, a large-scale study
should be developed to evaluate the accuracy of this method in clinical samples.
Here we described a proof-of-concept study of a novel SNP-based NIPAT through maternal
plasma DNA sequencing, which showed high accuracy in real clinical cases and may provide
an alternative in the application of noninvasive prenatal paternity testing in first trimester in
the future.
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Supporting Information
S1 Fig. Influence of MAF and the number of total SNPs to the number of effective SNP.
The number of effective SNPs had a positive correlation with the MAF and the number of total
SNPs in designed array.
(TIF)
S2 Fig. Influence of the cffDNA concentration and number of effective loci in the SNP-
based paternity test. In the boxplots, the y-axis marks the logarithmic value of combined
paternity index, and the x-axis stands for the concentration of cffDNA in the plasma. The plots
of a, b, c, d, e and f are corresponded to different number of effective loci, which is predicted in
the x-axis.
(TIF)
S3 Fig. Influence of the sequencing depth in the SNP-based paternity test. In the boxplots,
the y-axis marks the logarithmic value of CPI, and the x-axis stands for the sequencing depth
of the plasma. The plots of a, b, c, d, e and f are corresponded to different number of effective
loci, which is predicted in the x-axis.
(TIF)
S4 Fig. Influence of the number of effective SNPs in the low fetal fraction sample (S01,
effective sequencing depth = 40X). In the boxplots, the y-axis marks the logarithmic value of
combined paternity index, and the x-axis stands for the number of effective SNPs.
(TIF)
S1 File. Formula detail information.Detail information of PI calculation formula was listed
in the S1 file.
(DOCX)
S2 File. Loci information of three arrays.Detail loci information of three arrays was listed in
the S2 file.
(RAR)
S3 File. Supporting tables.All supporting Tables were listed in the S3 File. Table A listed the
clinical information of all samples. Table B listed the basic sequencing information of all sam-
ples. Table C listed the number of SNPs where assigned wrongly from the pool of potentially
informative SNPs for a tangible parents. Table D listed the information of effective depth and
the number of effective SNP of all samples. Table E listed the basic simulated information of
clinical samples.
(XLSX)
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